Inventiva S.A. American Depository Shares (IVA)
Stock · NASDAQ · Health Care
$2.95as of 10/16/2026
Price chart
Active signals
IVA Signal Track Record
How signals performed across all stocks →What IVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +3.8% | 58% | September 25, 2026 |
| Bollinger Band Breakout | 23 | -0.7% | 43% | August 7, 2026 |
| Bollinger Band Breakdown | 18 | -5.3% | 39% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -3.9% | 33% | April 30, 2026 |
| Any 20-session window (baseline) | -1.3% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odip…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 87
- Website
- inventivapharma.com/
Fundamentals
- 1-day range
- $2.91$3.14
- Market cap
- $1.10B
- P/E (trailing)
- —
- P/E (forward)
- -3.94
- EPS (trailing)
- $-2.29
- Dividend yield
- —
- Beta
- -0.42
- Avg. volume
- 1.55M
Forecasts
10 analyst ratings
Inventiva S.A. American Depository Shares Competitors
Chosen by industry and closest market cap.
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Earnings Scheduled For September 25, 2026benzinga · 9/25/2026
- Earnings Scheduled For September 25, 2026Benzinga · 9/25/2026
- Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · 9/21/2026
- Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
- Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14Benzinga · 9/15/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 52.32M
- Total value held
- $289.87M
- Institutional holders
- 65
- Unknown5.19M
- Unknown4.97M
- Unknown4.00M
- Unknown2.99M
- Unknown2.66M
- Unknown2.46M
- Unknown2.35M
- Unknown2.32M
- Unknown2.17M
- Unknown2.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Inventiva Faces Key Liver Disease Data Release
Inventiva is preparing to release pivotal data for its liver disease treatment, a major upcoming event for the company. Recent commentary highlights the stock's potential for significant movement following this readout. The shares currently trade near their 52-week low, with analysts maintaining higher average price targets.
Inventiva Faces Key Liver Disease Data Release. Inventiva is preparing to release pivotal data for its liver disease treatment, a major upcoming event for the company. Recent commentary highlights the stock's potential for significant movement following this readout. The shares currently trade near their 52-week low, with analysts maintaining higher average price targets.